Abstract

Chemical inducer of dimerization (CID) modules can be used effectively as molecular switches to control biological processes, and thus there is significant interest within the synthetic biology community in identifying novel CID systems. To date, CID modules have been used primarily in engineering cells for in vitro applications. To broaden their utility to the clinical setting, including the potential to control cell and gene therapies, the identification of novel CID modules should consider factors such as the safety and pharmacokinetic profile of the small molecule inducer, and the orthogonality and immunogenicity of the protein components. Here we describe a CID module based on the orally available, approved, small molecule simeprevir and its target, the NS3/4A protease from hepatitis C virus. We demonstrate the utility of this CID module as a molecular switch to control biological processes such as gene expression and apoptosis in vitro, and show that the CID system can be used to rapidly induce apoptosis in tumor cells in a xenograft mouse model, leading to complete tumor regression.

Chemical inducer of dimerization (CID) modules can be used to effectively control biological processes; however, CID modules have been explored primarily in engineering cells for in vitro applications using inducers that have limited clinical utility. Here, the authors identify a CID module with favorable properties to enable rapid translation from in vitro applications to potential use in humans.

Details

Title
A simeprevir-inducible molecular switch for the control of cell and gene therapies
Author
Chin, Stacey E. 1   VIAFID ORCID Logo  ; Schindler, Christina 1   VIAFID ORCID Logo  ; Vinall, Lisa 1 ; Dodd, Roger B. 2   VIAFID ORCID Logo  ; Bamber, Lisa 2 ; Legg, Sandrine 2 ; Sigurdardottir, Anna 2   VIAFID ORCID Logo  ; Rees, D. Gareth 2   VIAFID ORCID Logo  ; Malcolm, Tim I. M. 1 ; Spratley, Samantha J. 2 ; Granéli, Cecilia 3   VIAFID ORCID Logo  ; Sumner, Jonathan 1 ; Tigue, Natalie J. 1   VIAFID ORCID Logo 

 Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
 Biologics Engineering, Oncology R&D, AstraZeneca, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
 Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, BioPharmaceuticals R&D Cell Therapy Department, Research and Early Development, Gothenburg, Sweden (GRID:grid.418151.8) (ISNI:0000 0001 1519 6403) 
Pages
7753
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2894164153
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.